跳至主要内容
临床试验/NCT01504282
NCT01504282已完成不适用

Mitomycin-c Application for Photorefractive Keratectomy

Shahid Beheshti University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2012年1月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
90
试验地点
1
主要终点
Central corneal endothelial cell density (ECD) 6 months after the PRK

研究概览

简要总结

To evaluate the safety and efficacy of 5 seconds mitomycin-C (MMC) application during photorefractive keratectomy (PRK) for patients with low myopia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • The inclusion criteria was ablation depth less than 65 µm,
  • a stable refractive error for at least 1 year
  • corrected distance visual acuity (CDVA) of 0.1 LogMAR or better.

排除标准

  • Patients with keratoconus suspect,
  • excessive dry eyes,
  • impaired wound healing processes,
  • lenticular changes,
  • corneal dystrophy,
  • history of ocular surgery,
  • anterior or posterior uveitis,
  • glaucoma and retinal diseases were excluded.

研究组 & 干预措施

MMC group

Active Comparator

One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.

干预措施: mitomycin-C (Drug)

BSS group

Placebo Comparator

One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.

干预措施: Placebo (Drug)

结局指标

主要结局

Central corneal endothelial cell density (ECD) 6 months after the PRK

时间窗: 6 months

次要结局

未报告次要终点

研究者

研究点 (1)

Loading locations...

相似试验

Mitomycin-c Application for PRK | 临床试验